Deferiprone NDC 0054-0711

NDC codes

FDA NDC Directory

Product NDC (as listed)0054-0711Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00054-0711Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0054-0711-19	00054071119	50 TABLET, COATED in 1 BOTTLE (0054-0711-19)Marketed from Feb 8, 2022
0054-0711-23	00054071123	150 TABLET, COATED in 1 BOTTLE (0054-0711-23)Marketed from Feb 8, 2022
0054-0711-28	00054071128	300 TABLET, COATED in 1 BOTTLE (0054-0711-28)Marketed from Feb 8, 2022

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deferiprone
Generic name (nonproprietary): deferiprone
Active ingredients: Deferiprone — 1000 mg/1
Dosage form: Tablet, Coated
Route: Oral
Labeler: Hikma Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213239
Marketing start: Feb 8, 2022
Listing expires: Dec 31, 2026
Other FDA classes: Iron Chelating Activity (Mechanism)
Identifiers: Product ID 0054-0711_db72caee-70a3-4561-b855-08b4c9f4a0e0SPL ID db72caee-70a3-4561-b855-08b4c9f4a0e0SPL set ID c4f9e9be-39e7-4940-9cb0-f17772d7e524RxCUI 2180997UNII 2BTY8KH53LUPC 0300540711191
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400054071119 followed by a unit qualifier and the quantity

Package 00054-0711-19. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 1, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Limitations of Use: • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Pediatric use information is approved for Chiesi USA, Inc.’s FERRIPROX ® (deferiprone) tablets. However, due to Chiesi USA, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. Deferiprone tablets are an iron chelator indicated for the treatment of transfusional iron overload …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213239

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213239
Product	Strength	Form · route	Labeler	Product NDC
Deferiprone	Deferiprone 500 mg/1	Tablet, CoatedOral	Hikma Pharmaceuticals USA Inc.	0054-0576